drugset

drugset / Trial / NCT00254462

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

NCT00254462 ↗

Phase 4 Completed 93 enrolled University of Nebraska National Institute of Mental Health (NIMH) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) in young children.

Timeline

Start: 2005-10-01
Primary completion: 2008-08-01
Completion: 2008-09-01

Publications

Results Kratochvil CJ, Vaughan BS, Stoner JA, Daughton JM, Lubberstedt BD, Murray DW, Chrisman AK, Faircloth MA, Itchon-Ramos NB, Kollins SH, Maayan LA, Greenhill LL, Kotler LA, Fried J, March JS. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011 Apr;127(4):e862-8. doi: 10.1542/peds.2010-0825. Epub 2011 Mar 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atomoxetine	Other / unclassified	1.8 mg/kg	—

Indications